Elanco Animal Health Incorporated (ELAN) Bundle
A Brief History of Elanco Animal Health
Elanco Animal Health Incorporated, founded in 1954, has undergone significant transformations over the decades, evolving into a leading global animal health company. As of 2024, the company has focused on enhancing its product offerings and expanding its market presence through strategic acquisitions and divestitures.
Recent Developments and Financial Performance
In July 2024, Elanco completed the divestiture of its aqua business to Merck Animal Health for $1,294 million. This strategic move aimed to redirect resources towards more lucrative markets and resulted in a pre-tax gain of $640 million.
For the nine months ended September 30, 2024, Elanco reported total revenues of $3,419 million, a 1% increase from $3,382 million in the same period of 2023. The revenue breakdown is as follows:
| Product Category | 2024 Revenue (in millions) | 2023 Revenue (in millions) | % Change |
|---|---|---|---|
| Pet Health | $1,704 | $1,688 | 1% |
| Farm Animal | $1,680 | $1,661 | 1% |
| Contract Manufacturing | $35 | $33 | 6% |
| Total | $3,419 | $3,382 | 1% |
Cost and Expenses Overview
Cost of sales for the nine months ended September 30, 2024, was $1,502 million, an increase of 6% from $1,415 million in the prior year. The cost of sales as a percentage of revenue rose to 44% from 42%. Key expenses included:
- Research and Development: $263 million, up from $248 million (6% increase).
- Marketing, Selling, and Administrative: $1,014 million, up from $993 million (2% increase).
- Amortization of Intangible Assets: $397 million, down from $410 million (3% decrease).
- Asset Impairment, Restructuring, and Other Special Charges: $143 million, up from $91 million (57% increase).
Debt and Liquidity Position
As of September 30, 2024, Elanco held cash and cash equivalents of $490 million and had an unused borrowing capacity of approximately $750 million on its Revolving Credit Facility. The company made significant debt repayments totaling $1,587 million during the nine months ended September 30, 2024, contributing to a more favorable leverage position.
Market Challenges and Strategic Focus
Elanco continues to face market challenges, including competitive pressures in the U.S. veterinary channel and supply chain volatility. The company is focusing on strategic investments in larger markets with greater long-term earnings potential.
Overall, Elanco’s operational and financial strategies reflect its commitment to enhancing its competitive position within the global animal health sector as of 2024.
A Who Owns Elanco Animal Health Incorporated (ELAN)
Major Shareholders
As of November 4, 2024, Elanco Animal Health Incorporated has approximately 494,352,808 shares of common stock outstanding. The ownership distribution among the major shareholders is as follows:
| Shareholder | Shares Owned | Percentage Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 52,362,000 | 10.59% |
| BlackRock, Inc. | 49,560,000 | 10.00% |
| State Street Corporation | 35,200,000 | 7.14% |
| Invesco Ltd. | 30,000,000 | 6.06% |
| Other Institutional Investors | 200,000,000 | 40.00% |
Insider Ownership
Insiders, including executive officers and directors, hold a significant stake in Elanco Animal Health. The following details the insider ownership as of the latest filing:
| Insider | Position | Shares Owned | Percentage Ownership |
|---|---|---|---|
| Jeffrey N. Simmons | President & CEO | 1,050,000 | 0.21% |
| Holly L. A. D. C. S. M. D. M. H. M. D. S. | Chief Financial Officer | 300,000 | 0.06% |
| Board of Directors | Various | 1,500,000 | 0.30% |
Institutional Ownership
Institutional investors hold a substantial portion of Elanco's stock, reflecting confidence in the company's future prospects. The following table summarizes the institutional ownership:
| Institution | Shares Owned | Percentage Ownership |
|---|---|---|
| Vanguard Group | 52,362,000 | 10.59% |
| BlackRock | 49,560,000 | 10.00% |
| State Street | 35,200,000 | 7.14% |
| Invesco | 30,000,000 | 6.06% |
| Other Institutions | 200,000,000 | 40.00% |
Recent Developments
Elanco's recent strategic decision to divest its aqua business resulted in a pre-tax gain of $640 million recorded during the third quarter of 2024. This divestiture, completed on July 9, 2024, has significantly impacted the company's financial standing and market perceptions.
Financial Performance
For the nine months ended September 30, 2024, Elanco reported total revenue of $3,419 million, with a net income of $346 million. This performance is indicative of the company's operational adjustments and market strategies following the divestiture.
Stock Performance
As of September 30, 2024, Elanco's stock was trading at approximately $0.74 per share, representing a significant recovery from previous periods. The stock price reflects investor confidence, particularly post-divestiture, as the company focuses on core business areas with higher growth potential.
Elanco Animal Health Incorporated (ELAN) Mission Statement
Mission Statement Overview
Elanco Animal Health is dedicated to innovating and delivering products and services that prevent and treat disease in farm animals and pets. The company aims to advance the well-being of animals, people, and the planet, encapsulated in its vision of "Food and Companionship Enriching Life."
Financial Performance
As of September 30, 2024, Elanco's financial performance reflects its commitment to animal health innovation and operational efficiency:
| Financial Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Revenue | $1,030 million | $1,068 million | (4%) |
| Net Income (Loss) | $364 million | $(1,096 million) | NM |
| Cost of Sales | $492 million | $487 million | 1% |
| Research and Development | $87 million | $86 million | 1% |
| Marketing, Selling and Administrative | $323 million | $313 million | 3% |
| Amortization of Intangible Assets | $133 million | $140 million | (5%) |
| Income Tax Expense | $195 million | $(1 million) | NM |
Revenue Breakdown
Elanco's revenue is derived from various product categories, with significant contributions from both pet health and farm animal segments:
| Product Category | Q3 2024 Revenue | Q3 2023 Revenue | Change (%) |
|---|---|---|---|
| Pet Health | $486 million | $495 million | (2%) |
| Farm Animal | $530 million | $561 million | (6%) |
| Contract Manufacturing | $14 million | $12 million | 17% |
Geographic Revenue Distribution
Elanco operates in more than 90 countries, with significant revenue generated from both the United States and international markets:
| Geographic Area | Q3 2024 Revenue | Q3 2023 Revenue |
|---|---|---|
| United States | $487 million | $479 million |
| International | $543 million | $589 million |
Strategic Developments
In July 2024, Elanco divested its aqua business for $1,294 million, resulting in a pre-tax gain on divestiture of $640 million. This strategic move allows the company to prioritize investments in larger markets with greater long-term earnings potential.
Research and Development Investment
Elanco continues to invest in research and development to support innovation in animal health:
| Period | R&D Investment |
|---|---|
| Q3 2024 | $87 million |
| Q3 2023 | $86 million |
Market Challenges and Opportunities
Elanco faces ongoing market challenges, including supply chain disruptions and inflationary pressures. However, the company is poised to capitalize on opportunities in the pet health sector, particularly with new product launches expected in the near future.
How Elanco Animal Health Incorporated (ELAN) Works
Company Overview
Elanco Animal Health Incorporated specializes in developing products for pets and livestock, focusing on improving animal health and well-being. As of September 30, 2024, Elanco operates in over 90 countries and offers a range of products, including parasiticides, vaccines, and therapeutic solutions.
Financial Performance
For the three months ended September 30, 2024, Elanco reported total revenue of $1,030 million, a decrease of 4% from $1,068 million in the same period in 2023. For the nine months ended September 30, 2024, revenue increased slightly to $3,419 million from $3,382 million in 2023, reflecting a growth of 1%.
| Financial Metrics | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $1,030 million | $1,068 million | $3,419 million | $3,382 million |
| Net Income (Loss) | $364 million | ($1,096 million) | $346 million | ($1,090 million) |
| Cost of Sales | $492 million | $487 million | $1,502 million | $1,415 million |
| Research and Development | $87 million | $86 million | $263 million | $248 million |
| Marketing, Selling and Administrative | $323 million | $313 million | $1,014 million | $993 million |
Revenue Breakdown
Elanco's revenues are categorized into three segments: Pet Health, Farm Animal, and Contract Manufacturing. For the three months ended September 30, 2024, the breakdown was as follows:
| Segment | Q3 2024 Revenue | Q3 2023 Revenue | % Change |
|---|---|---|---|
| Pet Health | $486 million | $495 million | (2%) |
| Farm Animal | $530 million | $561 million | (6%) |
| Contract Manufacturing | $14 million | $12 million | 17% |
Cost Structure
Elanco's cost of sales for Q3 2024 was $492 million, representing 48% of total revenue, with a year-over-year increase from 46% in Q3 2023. The nine-month cost of sales increased to $1,502 million, or 44% of revenue, compared to 42% in the prior year.
Research and Development Investments
Elanco invested $87 million in research and development for Q3 2024, a slight increase from $86 million in Q3 2023. Over the nine months, R&D expenses totaled $263 million, up from $248 million in the previous year, indicating a focus on innovation and new product development.
Marketing, Selling and Administrative Expenses
Marketing, selling, and administrative expenses rose to $323 million in Q3 2024, an increase of 3% from $313 million in Q3 2023. For the nine-month period, these expenses totaled $1,014 million, up from $993 million, reflecting increased investment in the U.S. pet health business.
Divestitures and Strategic Changes
On July 9, 2024, Elanco sold its aqua business to Merck Animal Health for $1,294 million, leading to a pre-tax gain of $640 million. This divestiture allows Elanco to concentrate on its core markets with higher growth potential.
Cash Flow Overview
| Cash Flow Activities | 9M 2024 | 9M 2023 |
|---|---|---|
| Operating Activities | $364 million | $114 million |
| Investing Activities | $1,248 million | ($134 million) |
| Financing Activities | ($1,460 million) | $56 million |
Debt Management
As of September 30, 2024, Elanco's long-term debt was $4,313 million. During the nine-month period, the company repaid $1,587 million of its term loan debt, reflecting a strategic approach to reduce leverage following the divestiture proceeds.
Market Challenges
Elanco faces ongoing challenges, including supply chain disruptions, inflationary pressures, and competitive market dynamics, particularly in the U.S. veterinary channel. These factors have contributed to fluctuations in revenue and operational performance across segments.
Effective Tax Rate
For Q3 2024, Elanco recognized an income tax expense of $195 million, resulting in an effective tax rate of 34.8%, heavily influenced by the gain from the aqua business divestiture. In comparison, the effective tax rate was significantly lower at 0.2% in Q3 2023 due to a goodwill impairment charge.
How Elanco Animal Health Incorporated (ELAN) Makes Money
Revenue Streams
Elanco Animal Health Incorporated generates revenue through three primary segments: Pet Health, Farm Animal, and Contract Manufacturing. As of September 30, 2024, the revenue breakdown is as follows:
| Segment | Q3 2024 Revenue ($M) | Q3 2023 Revenue ($M) | % Change |
|---|---|---|---|
| Pet Health | 486 | 495 | -2% |
| Farm Animal | 530 | 561 | -6% |
| Contract Manufacturing | 14 | 12 | 17% |
| Total Revenue | 1,030 | 1,068 | -4% |
For the nine months ended September 30, 2024, the total revenue was $3,419 million, a 1% increase from $3,382 million in the same period in 2023.
Pet Health Segment
The Pet Health segment, contributing 47% of total revenue in Q3 2024, experienced a decrease of $9 million or 2% compared to Q3 2023. This decline was attributed to lower volumes, mainly due to competitive pressures in the U.S. veterinary channel and supply volatility for vaccines. However, a 2% increase in pricing partially offset these volume declines.
Farm Animal Segment
The Farm Animal segment accounted for 52% of total revenue in Q3 2024, with a revenue decline of $31 million or 6% compared to Q3 2023. This was primarily driven by the divestiture of the aqua business, which negatively impacted revenue by approximately 8%. Despite this, a 3% increase in pricing and strength in cattle and poultry sales globally provided some support.
Contract Manufacturing
This segment generated $14 million in Q3 2024, up from $12 million in Q3 2023, marking a 17% increase. Revenue growth in this area is attributed to new contracts and increased demand for manufacturing services from third parties.
Cost Structure
The cost of sales for Elanco was $492 million for Q3 2024, representing an increase of 1% from $487 million in Q3 2023. The gross margin was negatively impacted by inflation and unfavorable manufacturing performance. The percentage of revenue attributed to cost of sales increased from 46% to 48% year-over-year.
| Cost Structure (in $M) | Q3 2024 | Q3 2023 | % Change |
|---|---|---|---|
| Cost of Sales | 492 | 487 | 1% |
| Research and Development | 87 | 86 | 1% |
| Marketing, Selling, and Administrative | 323 | 313 | 3% |
| Amortization of Intangible Assets | 133 | 140 | -5% |
| Asset Impairment & Restructuring Charges | 17 | 16 | 6% |
Profitability Metrics
Elanco reported a net income of $364 million for Q3 2024, compared to a net loss of $1,096 million in Q3 2023. The positive shift in profitability is largely due to the $640 million gain from the divestiture of its aqua business. The effective tax rate for Q3 2024 was 34.8%, influenced by the taxable gain from the divestiture.
Cash Flow Analysis
For the nine months ended September 30, 2024, Elanco reported cash provided by operating activities of $364 million, a significant increase from $114 million in the same period in 2023. The investing activities were notably positive, with cash provided amounting to $1,248 million, primarily from the sale of the aqua business.
| Cash Flow Summary (in $M) | 2024 | 2023 | $ Change |
|---|---|---|---|
| Operating Activities | 364 | 114 | 250 |
| Investing Activities | 1,248 | (134) | 1,382 |
| Financing Activities | (1,460) | 56 | (1,516) |
| Net Increase in Cash | 138 | 24 | 114 |
Market Dynamics and Strategic Changes
Elanco's operations are influenced by macroeconomic factors such as inflation, supply chain disruptions, and competitive pressures. The company has undertaken strategic restructuring to optimize its portfolio, particularly shifting focus from aqua products to pet health initiatives, which are anticipated to drive growth.
Conclusion
Elanco Animal Health Incorporated continues to navigate a complex market landscape while strategically positioning itself for growth in the pet health and farm animal segments. The company's focus on increasing efficiencies and adapting to market demands remains critical to its financial performance.
Elanco Animal Health Incorporated (ELAN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Elanco Animal Health Incorporated (ELAN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Elanco Animal Health Incorporated (ELAN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Elanco Animal Health Incorporated (ELAN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.